1. Executive Summary (Confidence: High)

FimmCyte is a clinical-stage ready biotechnology spin-off from the University of Zurich (UZH) and University Hospital Zurich (USZ), founded in 2022. The organization is pioneering a "Blue Ocean" in women's health by moving beyond traditional symptom management toward disease-modifying therapies for endometriosis and broader fibro-inflammatory conditions. Its core innovation is a proprietary antibody platform based on the "Deplete. Reprogram. Regenerate" principle, which targets specific proteins overexpressed in diseased cells to reverse fibrosis. In early 2026, FimmCyte secured a landmark strategic collaboration and option-to-license agreement with Gedeon Richter, a global leader in women's health, to accelerate its lead candidate, FMC2, into human clinical trials. With over $7 million in total funding and a lean, high-expertise team, FimmCyte is positioned as a critical innovator at the intersection of women's health and the longevity ecosystem's focus on targeted fibrosis reversal.